Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients
Caveolin-1 (Cav-1) plays a key role in various neoplastic diseases and is upregulated in different cancers, including pancreatic ductal adenocarcinoma (PDAC). Furthermore, Cav-1 is critical for the uptake of albumin as well as nab-paclitaxel in PDAC cells. Here, we investigated the prognostic impact...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/28/5/303 |
| _version_ | 1827679859501957120 |
|---|---|
| author | Alessandro Bittoni Riccardo Giampieri Federica Pecci Giada Pinterpe Alessandra Mandolesi Michela Del Prete Antonio Zizzi Sonia Crocetti Carolina Liguori Giulia Mentrasti Luca Cantini Chiara Pellei Renato Bisonni Marina Scarpelli Rossana Berardi |
| author_facet | Alessandro Bittoni Riccardo Giampieri Federica Pecci Giada Pinterpe Alessandra Mandolesi Michela Del Prete Antonio Zizzi Sonia Crocetti Carolina Liguori Giulia Mentrasti Luca Cantini Chiara Pellei Renato Bisonni Marina Scarpelli Rossana Berardi |
| author_sort | Alessandro Bittoni |
| collection | DOAJ |
| description | Caveolin-1 (Cav-1) plays a key role in various neoplastic diseases and is upregulated in different cancers, including pancreatic ductal adenocarcinoma (PDAC). Furthermore, Cav-1 is critical for the uptake of albumin as well as nab-paclitaxel in PDAC cells. Here, we investigated the prognostic impact of Cav-1 expression in a cohort of 39 metastatic PDAC patients treated with different first-line chemotherapy regimens. We also assessed the predictive value of Cav-1 in patients treated with gemcitabine and nab-paclitaxel. Cav-1 expression was evaluated by immunohistochemistry staining in neoplastic and stromal cells, using metastatic sites or primary tumor tissue specimens. Higher levels of Cav-1 expression were associated with significantly worse overall survival (OS) and progression-free survival (PFS). No differences in OS were found between patients treated with gemcitabine + nab-paclitaxel vs. other chemotherapy options. Multivariate analysis for OS and PFS confirmed the independent prognostic role of Cav-1 expression. Our study evidenced a negative prognostic role of Cav-1 in patients affected by metastatic/locally advanced unresectable PDAC. Moreover, Cav-1 expression seems not to predict different response rates to different types of first-line treatment. Future prospective trials will be necessary to confirm the prognostic role of Cav-1 and explore Cav-1 specific inhibitors as a therapeutic option for advanced PDAC patients. |
| first_indexed | 2024-03-10T06:38:04Z |
| format | Article |
| id | doaj.art-eb8e120972bf489ea1cff21db2076297 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-10T06:38:04Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-eb8e120972bf489ea1cff21db20762972023-11-22T17:54:39ZengMDPI AGCurrent Oncology1198-00521718-77292021-09-012853525353610.3390/curroncol28050303Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer PatientsAlessandro Bittoni0Riccardo Giampieri1Federica Pecci2Giada Pinterpe3Alessandra Mandolesi4Michela Del Prete5Antonio Zizzi6Sonia Crocetti7Carolina Liguori8Giulia Mentrasti9Luca Cantini10Chiara Pellei11Renato Bisonni12Marina Scarpelli13Rossana Berardi14Medical Oncology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, Università Politecnica delle Marche, 60126 Ancona, ItalyMedical Oncology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, Università Politecnica delle Marche, 60126 Ancona, ItalyMedical Oncology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, Università Politecnica delle Marche, 60126 Ancona, ItalyMedical Oncology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, Università Politecnica delle Marche, 60126 Ancona, ItalyDepartment of Pathological Anatomy and Histopathology, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, 60126 Ancona, ItalyMedical Oncology Unit, Ospedale A. Murri, 63900 Fermo, ItalyDepartment of Pathological Anatomy and Histopathology, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, 60126 Ancona, ItalyMedical Oncology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, Università Politecnica delle Marche, 60126 Ancona, ItalyMedical Oncology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, Università Politecnica delle Marche, 60126 Ancona, ItalyMedical Oncology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, Università Politecnica delle Marche, 60126 Ancona, ItalyMedical Oncology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, Università Politecnica delle Marche, 60126 Ancona, ItalyMedical Oncology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, Università Politecnica delle Marche, 60126 Ancona, ItalyMedical Oncology Unit, Ospedale A. Murri, 63900 Fermo, ItalyDepartment of Pathological Anatomy and Histopathology, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, 60126 Ancona, ItalyMedical Oncology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, Università Politecnica delle Marche, 60126 Ancona, ItalyCaveolin-1 (Cav-1) plays a key role in various neoplastic diseases and is upregulated in different cancers, including pancreatic ductal adenocarcinoma (PDAC). Furthermore, Cav-1 is critical for the uptake of albumin as well as nab-paclitaxel in PDAC cells. Here, we investigated the prognostic impact of Cav-1 expression in a cohort of 39 metastatic PDAC patients treated with different first-line chemotherapy regimens. We also assessed the predictive value of Cav-1 in patients treated with gemcitabine and nab-paclitaxel. Cav-1 expression was evaluated by immunohistochemistry staining in neoplastic and stromal cells, using metastatic sites or primary tumor tissue specimens. Higher levels of Cav-1 expression were associated with significantly worse overall survival (OS) and progression-free survival (PFS). No differences in OS were found between patients treated with gemcitabine + nab-paclitaxel vs. other chemotherapy options. Multivariate analysis for OS and PFS confirmed the independent prognostic role of Cav-1 expression. Our study evidenced a negative prognostic role of Cav-1 in patients affected by metastatic/locally advanced unresectable PDAC. Moreover, Cav-1 expression seems not to predict different response rates to different types of first-line treatment. Future prospective trials will be necessary to confirm the prognostic role of Cav-1 and explore Cav-1 specific inhibitors as a therapeutic option for advanced PDAC patients.https://www.mdpi.com/1718-7729/28/5/303Caveolin-1pancreatic cancer1st line chemotherapyprognosis |
| spellingShingle | Alessandro Bittoni Riccardo Giampieri Federica Pecci Giada Pinterpe Alessandra Mandolesi Michela Del Prete Antonio Zizzi Sonia Crocetti Carolina Liguori Giulia Mentrasti Luca Cantini Chiara Pellei Renato Bisonni Marina Scarpelli Rossana Berardi Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients Current Oncology Caveolin-1 pancreatic cancer 1st line chemotherapy prognosis |
| title | Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients |
| title_full | Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients |
| title_fullStr | Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients |
| title_full_unstemmed | Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients |
| title_short | Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients |
| title_sort | retrospective cohort study of caveolin 1 expression as prognostic factor in unresectable locally advanced or metastatic pancreatic cancer patients |
| topic | Caveolin-1 pancreatic cancer 1st line chemotherapy prognosis |
| url | https://www.mdpi.com/1718-7729/28/5/303 |
| work_keys_str_mv | AT alessandrobittoni retrospectivecohortstudyofcaveolin1expressionasprognosticfactorinunresectablelocallyadvancedormetastaticpancreaticcancerpatients AT riccardogiampieri retrospectivecohortstudyofcaveolin1expressionasprognosticfactorinunresectablelocallyadvancedormetastaticpancreaticcancerpatients AT federicapecci retrospectivecohortstudyofcaveolin1expressionasprognosticfactorinunresectablelocallyadvancedormetastaticpancreaticcancerpatients AT giadapinterpe retrospectivecohortstudyofcaveolin1expressionasprognosticfactorinunresectablelocallyadvancedormetastaticpancreaticcancerpatients AT alessandramandolesi retrospectivecohortstudyofcaveolin1expressionasprognosticfactorinunresectablelocallyadvancedormetastaticpancreaticcancerpatients AT micheladelprete retrospectivecohortstudyofcaveolin1expressionasprognosticfactorinunresectablelocallyadvancedormetastaticpancreaticcancerpatients AT antoniozizzi retrospectivecohortstudyofcaveolin1expressionasprognosticfactorinunresectablelocallyadvancedormetastaticpancreaticcancerpatients AT soniacrocetti retrospectivecohortstudyofcaveolin1expressionasprognosticfactorinunresectablelocallyadvancedormetastaticpancreaticcancerpatients AT carolinaliguori retrospectivecohortstudyofcaveolin1expressionasprognosticfactorinunresectablelocallyadvancedormetastaticpancreaticcancerpatients AT giuliamentrasti retrospectivecohortstudyofcaveolin1expressionasprognosticfactorinunresectablelocallyadvancedormetastaticpancreaticcancerpatients AT lucacantini retrospectivecohortstudyofcaveolin1expressionasprognosticfactorinunresectablelocallyadvancedormetastaticpancreaticcancerpatients AT chiarapellei retrospectivecohortstudyofcaveolin1expressionasprognosticfactorinunresectablelocallyadvancedormetastaticpancreaticcancerpatients AT renatobisonni retrospectivecohortstudyofcaveolin1expressionasprognosticfactorinunresectablelocallyadvancedormetastaticpancreaticcancerpatients AT marinascarpelli retrospectivecohortstudyofcaveolin1expressionasprognosticfactorinunresectablelocallyadvancedormetastaticpancreaticcancerpatients AT rossanaberardi retrospectivecohortstudyofcaveolin1expressionasprognosticfactorinunresectablelocallyadvancedormetastaticpancreaticcancerpatients |